VEGF-specific capture agents, compositions, and methods of using and making
The present application provides biligand and triligand protein-catalyzed capture (PCC) agents that specifically bind VEGF, as well as the use of these capture agents as detection, diagnosis, and treatment agents.
1. A stable, synthetic capture agent that specifically binds VEGF, wherein the capture agent comprises a designed anchor ligand, a designed secondary ligand, and, optionally, a designed tertiary ligand, and wherein the anchor ligand and secondary ligand selectively bind VEGF, wherein the anchor ligand comprises an amino acid sequence 95% identical to the amino acid sequence of SEQ ID NO:1 and wherein the secondary ligand comprises a formula of X2-X3-X4-X5-X6, wherein X2 is selected from the group consisting of D-arginine, D-tryptophan, D-leucine, D-valine, glycine, D-proline, D-isoleucine and D-alanine; wherein X3 is selected from the group consisting of D-proline, D-phenylalanine, glycine, D-arginine, D-lysine, D-histidine, D-tryptophan and D-tyrosine; wherein X4 is selected from the group consisting of D-isoleucine, D-leucine, D-proline, D-alanine, D-arginine, D-phenylalanine, D-threonine and D-histidine; wherein X5 is selected from the group consisting of D-isoleucine, glycine, D-valine, D-leucine, D-alanine, D-proline, D-lysine, D-glutamate, D-histidine and D-arginine; and wherein X6 is selected from the group consisting of D-arginine, D-lysine, D-tryptophan, D-tyrosine, D-proline, D-valine, glycine, D-isoleucine, D-alanine and D-glutamine.
2. The capture agent of claim 1 , wherein the anchor ligand and secondary ligand are linked together via a 1,4-substituted-1,2,3-triazole residue (Tz4).
3. The capture agent of claim 1 , wherein the capture agent has a structure selected from the group consisting of:
wherein R is a pegylated reporter tag or an N-terminal capping group.
4. The capture agent of claim 1 , further comprising a designed tertiary ligand,
wherein the tertiary ligand comprises a formula of X2-X3-X4-X5-X6 wherein
X2 is selected from the group consisting of D-histidine, D-arginine and D-lysine; X3 is selected from the group consisting of D-threonine, D-asparagine, D-leucine, D-proline, D-isoleucine, D-alanine, and D-glutamate; X4 is selected from the group consisting of D-histidine, D-lysine, D-arginine, D-tryptophan, D-phenylalanine, D-proline, D-leucine and D-tyrosine; X5 is selected from the group consisting of D-valine, D-proline, D-histidine, D-phenylalanine, D-tryptophan, D-asparagine, D-glutamine, D-serine and D-tyrosine; and X6 is selected from the group consisting of D-arginine, D-tyrosine, D-asparagine, D-glutamine, D-leucine, D-proline, D-lysine and D-histidine;
X2 is selected from the group consisting of D-tyrosine, D-phenylalanine and D-tryptophan; X3 is selected from the group consisting of D-proline, D-alanine, glycine, D-leucine, D-lysine, D-arginine and D-histidine; X4 is selected from the group consisting of D-arginine, D-histidine, D-tryptophan, D-phenylalanine, D-glutamate, D-proline, D-serine and D-threonine; X5 is selected from the group consisting of D-proline, D-aspartate, D-lysine, D-arginine, D-tyrosine, D-histidine, D-alanine, D-valine, D-leucine and D-asparagine; and X6 is selected from the group consisting of D-histidine, D-lysine, D-asparagine, D-threonine, D-glutamine, D-leucine, D-aspartate, D-serine, D-tyrosine, D-arginine, D-tryptophan, D-glutamate and D-valine; or
X2 is selected from the group consisting of D-glutamate and D-aspartate; X3 is Selected from the group consisting of D-glutamate, D-phenylalanine, D-tryptophan, D-histidine, D-lysine, D-asparagine and D-serine; X4 is selected from the group consisting of D-isoleucine, D-proline, D-alanine, D-arginine, D-serine, D-aspartate, D-asparagine, D-proline, D-phenylalanine, D-tyrosine and D-histidine; X5 is selected from the group consisting of D-arginine, D-tyrosine, glycine, D-tryptophan, D-lysine, D-histidine, D-alanine, D-asparagine and D-leucine; and X6 is selected from the group consisting of D-aspartate, D-proline, D-tryptophan, D-tyrosine, D-leucine, D-asparagine, D-serine and D-threonine.
5. The capture agent of claim 4 , wherein the anchor ligand and secondary ligand are linked together via a 1,4-substituted-1,2,3-triazole residue (Tz4).
6. The capture agent of claim 4 , wherein the secondary ligand and tertiary ligand are linked together via a 1,4-substituted-1,2,3-triazole residue (Tz4).
7. The capture agent of claim 4 , wherein the capture agent has a structure selected from the group consisting of
wherein R is a pegylated reporter tag or an N-terminal capping group.
8. The capture agent of claim 4 , wherein binding of said capture agent to VEGF inhibits VEGF activity.
9. The capture agent of claim 4 , wherein said capture agent inhibits binding of VEGF to VEGF receptor (VEGFR).
10. The capture agent of claim 4 , wherein the capture agent is stable at a temperature of about about −80° C. to about 40° C.
11. The capture agent of claim 4 , wherein the capture agent is stable at room temperature.
12. The capture agent of claim 4 , wherein the capture agent is stable in blood serum or blood plasma for at least 24 hours.
13. The capture agent of claim 4 , wherein the capture agent is stable at a pH in the range of from about 3 to about 12.
14. The capture agent of claim 4 , wherein the capture agent is labeled with a label selected from the group consisting of biotin and copper-DOTA.
15. A method of detecting VEGF in a biological sample using an immunoassay, wherein the immunoassay utilizes a capture agent of claim 1 or claim 4 , and wherein said capture agent replaces an antibody or its equivalent in the immunoassay.
16. The method of claim 15 , wherein the immunoassay is selected from the group of Western blot, pull-down assay, dot blot, and ELISA.
17. A method of treating a condition associated with increased VEGF expression and/or activity in a subject in need thereof, comprising administering a therapeutically effective amount of a capture agent of claim 4 .
18. The method of claim 17 , wherein said condition is selected from the group consisting of cancer, proliferative retinopathy, disease pathology of wet form age-related macular degeneration (AMD), or rheumatoid arthritis.
19. A method of inhibiting VEGF activity in a subject comprising administering to the subject a therapeutically effective amount of the capture agent of claim 4 .
20. The capture agent of claim 4 , wherein the capture agent is labeled with the detectable moiety consisting of 64 Cu DOTA, 68 Ga DOTA, 18 F, 64 Cu, 68 Ga, 89 Zr, 124 I, 86 Y, 94m Tc, 110m In, 11 C or 76 Br.
21. A method of diagnosing a VEGF expressing cancer in a subject, the method comprising the steps of: a) administering to the subject the VEGF capture agent of claim 4 , linked to a detectable moiety; and b) detecting the moiety linked to the VEGF capture agent in the subject; wherein detection of the moiety diagnoses a VEGF-expressing cancer in the subject.
22. The method of claim 21 , wherein the capture agent is labeled with the detectable moiety consisting of 64 Cu DOTA, 68 Ga DOTA, 18 F, 64 Cu, 68 Ga, 89 Zr, 124 I, 86 Y, 94m Tc, 110 In, 11 C or 76 Br.
23. A method of monitoring treatment of a subject receiving VEGF-directed therapy comprising
a) administering to the patient a small-molecule positron-emission-tomography ligand (PET ligand) that is bound to the VEGF capture agent of claim 2 or claim 5 on or near a VEGF-expressing cancer in the subject;
b) measuring the PET ligand that is bound to the VEGF capture agent associated with the VEGF-associated cancer at a first time;
c) measuring the PET ligand that is bound to the VEGF capture agent associated with the VEGF-associated cancer at a second time; and
d) comparing the amount of PET ligand that is bound to the VEGF capture agent associated with the VEGF-associated cancer at the first and second times, thereby monitoring treatment of the subject receiving VEGF-directed therapy.
24. A method for detecting VEGF in a sample comprising a) exposing the sample to the VEGF capture agent of claim 4 , linked to a detectable moiety; and b) detecting the moiety linked to the VEGF capture agent in the sample; thereby detecting VEGF in the sample.
25. The method of claim 24 , wherein the capture agent is labeled with the detectable moiety consisting of 64 Cu DOTA, 68 Ga DOTA, 18 F, 64 Cu, 68 Ga, 89 Zr, 124 I, 86 Y, 94m Tc, 110m In, 11 C or 76 Br.
26. The method of claim 24 , wherein the moiety linked to the VEGF capture agent is detected using PET or SPECT.
27. The method of claim 22 , wherein the moiety linked to the VEGF capture agent is detected using PET or SPECT.
28. The capture agent of claim 3 , wherein the pegylated reporter tag is selected from the group consisting of biotin-PEG and DOTA-PEG.
29. The capture agent of claim 3 , wherein the N-terminal capping group is an acetyl group.
30. The capture agent of claim 7 , wherein the pegylated reporter tag is selected from the group consisting of biotin-PEG and DOTA-PEG.
31. The capture agent of claim 7 , wherein the N-terminal capping group is an acetyl group.
32. The capture agent of claim 14 , wherein the label is bound to the capture agent by a linker.
33. The capture agent of claim 32 , wherein the linker is a PEG linker.
34. The capture agent of claim 28 , wherein the biotin-PEG is biotin-PEG3.
35. The capture agent of claim 34 , wherein the biotin-PEG is biotin-PEG3.